



# Market Announcement

4 November 2021

---

## Amplia Therapeutics Limited (ASX: ATX) – Trading Halt

### Description

The securities of Amplia Therapeutics Limited ('ATX') will be placed in trading halt at the request of ATX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 8 November 2021 or when the announcement is released to the market.

### Issued by

**Alice Montefiore-King**

Adviser, Listings Compliance (Sydney)

4 November 2021

Ms. Alice Montefiore-King  
Adviser, Listings Compliance (Sydney)  
ASX Limited

### **Request for Trading Halt**

Pursuant to Listing Rule 17.1, Amplia Therapeutics Limited (ASX: ATX) (Amplia or the Company) requests that ASX grant a trading halt in the ordinary shares of the Company.

In accordance with Listing Rule 17.1, we advise that:

1. A Trading Halt is requested to allow Amplia to undertake a capital raising process.
2. Amplia requests that the trading halt remain in place for up to two days with normal trading to resume on Monday 8 November 2021.
3. Amplia will lodge an announcement for release to the market regarding the capital raising to end the trading halt.
4. Amplia is not aware of any reason why a Trading Halt should not be granted or of any other information necessary to inform the market or ASX in respect of these matters.

Please contact me if you require any further information.

Authorised by,  
**Andrew Cooke**  
**Company Secretary**  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

### **About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).